Seek Labs Announces Inclusion of Veterinary Diseases in Global Disease Atlas, Accelerating Development of Therapeutics to Bolster Global Protein Supply Chains

SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced the inclusion of veterinary pathogens in its Global Disease Atlas, tackling head-on one of global health’s most pressing challenges: safeguarding protein supply chains, which remain exposed to both endemic and emerging biological diseases. These threats directly undermine the resilience of food systems and lead to protein shortages, price volatility, and supply chain destabilization, causing billions in economic losses through culling, trade bans, and supply disruptions. African Swine Fever Virus (ASFV), Capripox (Lumpy Skin Disease, Sheep Pox, Goat Pox), and Classical Swine Fever (CSFV) are among the diseases already mapped by Seek Labs’ BioSeeker™ discovery engine to accelerate the development of targeted therapeutics.

African Swine Fever (ASFV), Capripox (Lumpy Skin Disease, Sheep Pox, Goat Pox), and Classical Swine Fever (CSFV) are among the diseases already mapped by Seek Labs’ BioSeeker™ discovery engine to accelerate the development of targeted therapeutics.

Share

From Genomic Mapping to Therapeutic Design: How BioSeeker Powers the Programmable Target Ablation Platform (PTAP)

BioSeeker™ scans thousands of publicly available genomic sequences to identify high-potential, PTAP-compatible targets essential for viral replication. These mapped targets form a blueprint intended to guide development of programmable, CRISPR-based ‘seek-and-destroy’ therapeutics that target the pathogen at its genetic core. This adaptability includes targeting both RNA and DNA viruses.

Progress in Veterinary Therapeutic Programs with PTAP

African Swine Fever Virus

African Swine Fever Virus represents an ongoing crisis that has caused over $100 billion in global economic losses, repeatedly disrupting pork production, which is a critical protein source worldwide. Seek Labs has developed an ASFV therapeutic candidate that successfully completed in vivo trials, demonstrating an increase from 0% survival to nearly 60% survival in animals challenged with lethal doses of the pandemic strain.

“Our in vivo ASFV trials demonstrated the first successful study in a veterinary model using a programmable therapeutic against a high-consequence foreign animal disease, showing our adaptable platform could be engineered as a countermeasure for other viral threats,” said Douglas Gladue, Seek Labs’ VP of Veterinary Pharmaceutical Development.

Capripox Viruses (Lumpy Skin Disease, Sheep and Goat Pox)

Capripox viruses cause widespread livestock outbreaks across continents, with cumulative losses estimated at over $1 billion globally in the past decade due to culling, trade bans, and production declines. These closely related pathogens—including Lumpy Skin Disease, Sheep Pox, and Goat Pox—belong to the same viral family (Capripox) and share highly conserved genomic regions. BioSeeker has identified targets supporting a potential pan-Capripox therapeutic to combat outbreaks across regions.

Classical Swine Fever (CSFV)

Classical Swine Fever (CSFV) is a persistent, highly contagious transboundary threat that has caused over $5 billion in estimated global economic losses in recent decades through trade restrictions, mass culling, and costly eradication campaigns.

Together, these veterinary targets demonstrate Seek Labs’ capacity to rapidly design, develop, and deliver programmable solutions for diverse, high-consequence threats with PTAP. This cross-species capability not only supports animal health but also strengthens global bio-surveillance and control infrastructure.

Partnering for a Holistic Global Health Solution

The inclusion of veterinary pathogens underscores Seek Labs’ commitment to global health by recognizing the interdependence of human and animal health. By building a robust, partner-ready repository of mapped genomic targets and combining BioSeeker’s precision mapping with its Programmable Target Ablation Platform, the company offers partners an efficient path to advance next-generation veterinary therapeutics. Seek Labs invites qualified partners to help deliver transformative solutions that improve health outcomes worldwide, strengthen food security infrastructure, and address a rapidly growing market need.

About Seek Labs

At Seek Labs, we don’t wait for change—we build it. We’re pursuing the breakthroughs the world can’t wait for by developing programmable “seek-and-destroy” therapeutics and point-of-care molecular diagnostics that close the gap between outbreak and intervention. At the core of this mission is a layered architecture: BioSeeker™ serves as the Intelligence Layer, continuously mapping conserved viral vulnerabilities in real time; these insights activate our Deployment Layers (PTAP™ for programmable therapeutics and SeekIt™ for molecular diagnostics), forming a full-stack development engine designed to accelerate response, innovation, and impact across global health.

Headquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah’s collaborative life sciences ecosystem. Together with our partners, we’re building faster, smarter solutions for the world’s most urgent health challenges.

Forward-Looking Statements and Regulatory Disclaimer

This press release includes forward-looking statements about Seek Labs’ technologies, development plans, and partnership opportunities. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ. The technologies described are investigational and have not been reviewed or approved by the FDA or any other regulatory authority for clinical or commercial use.